1	Impact of brain frailty on complications and outcomes
2	in acute ischemic stroke
3	XiaoQing Cheng ¹ , MD; Wu Cai ^{# 2} , MD; ChuYan Li ³ ,MM; Xi Shen ⁴ ,MM; JiaNan Li ⁵ ,MM;
4	LiJun Huang ⁶ ,MM; JinJing Tang ¹ ,BS; HuiMin Pang ¹ ,BS; BaiYan Luo ¹ ,BS; Ya Liu ¹ , MM;
5	QianChen ⁷ ,MD; Lulu Xiao ⁸ ,MD; WuSheng Zhu ⁸ ,MD; ZeHong Cao ⁹ , PhD; XiaoYu
6	Liu ¹⁰ ,MD; LongJiang Zhang ¹ ,MD; XinDao Yin ⁷ , MD; ZhiQiang Zhang ^{*1} , MD; Feng Shi * ⁹ ,
7	PhD; Wei Xing* ¹¹ ,MD ; GuangMing Lu ¹ ,MD
8	
9	Affiliations
10	1 Department of Medical Imaging, Nanjing Jinling Hospital, Nanjing University School of
11	Medicine, Nanjing, Jiangsu 210002, China
12	2 Department of Radiology, The Second Affiliated Hospital of Soochow University,
13	Suzhou,Jiangsu 215004, China
14	3 Department of Medical Imaging, Nanjing Jinling Hospital, XuZhou Medical University.
15	Nanjing, Jiangsu 210002, China.
16	4 Department of Medical Imaging, Nanjing Jinling Hospital, Nanjing Medical University,
17	Nanjing, Jiangsu 210002, China.
18	5 Department of Medical Imaging, Nanjing Jinling Hospital, Affiliated Hospital of Medical
19	School, Nanjing University, Nanjing, Jiangsu 210002, China
20	6 Department of Medical Imaging, Nanjing Jinling Hospital, the First School of Clinical
21	Medicine, Southern Medical University, Nanjing, Jiangsu 210002, China
22	7 Departments of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing,
23	Jiangsu 210002, China
24	8 Department of Neurology, Nanjing Jinling Hospital, Nanjing University School of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 Medicine, Nanjing, Jiangsu 210002, China
- 26 9 Department of Research and Development, Shanghai United Imaging Intelligence Co., Ltd.,
- 27 Shanghai 200232, China
- 10 Department of Radiology, Ganzhou People's Hospital, Ganzhou, Jiangxi 341000, China
- 29 11 Department of Radiology, Third Afliated Hospital of Soochow University, Changzhou,
- 30 Jiangsu 213000, China

31

32 Short title: Brain frailty impact in acute ischemic stroke

33

34 # XiaoQing Cheng, Wu Cai contributed equally to this work.

35

36 Correspondence

- 37 Wei Xing ; Co- correspondence: ZhiQiang Zhang and Feng Shi
- 38 Department of Radiology, Third Afliated Hospital of Soochow University, Changzhou,
- 39 Jiangsu 213000, China
- 40 E-Mail: suzhxingwei@suda.edu.cn; zhangzq2001@126.com;feng.shi@uii-ai.com

41

42 Manuscript word count: 4552

- 44
- 45
- 46
- 47

48	Impact of brain frailty on complications and outcomes
49	in acute ischemic stroke
50	ABSTRACT
51	BACKGROUND: This study aimed to determine the association of brain frailty with acute
52	complications and prognosis in patients with acute ischemic stroke (AIS) due to occlusion of
53	large vessels in the anterior circulation, and to further assess its predictive value.
54	METHODS AND RESULTS: This multicenter, retrospective study included patients with
55	AIS due to large vessel occlusion in the anterior circulation. All patients underwent MRI
56	within seven days of stroke onset, measuring subcortical and cortical atrophy and
57	leukoaraiosis as indicators of brain frailty. The study included 1,090 patients with a median
58	age of 64 (interquartile range, 55–73) years and a median National Institutes of Health Stroke
59	Scale (NIHSS) score of 9 (interquartile range, 4.5–15). Multivariable logistic regression
60	analysis showed that independent risk factors for the unfavorable clinical outcome included:
61	NIHSS score (OR, 1.17; 95% CI, 1.13–1.22), blood glucose (OR, 1.15; 95% CI, 1.04–1.26),
62	infarct volume (OR, 1.32; 95% CI, 1.15–1.52), subcortical atrophy (OR, 1.27; 95% CI, 1.18–
63	1.37), severe cortical atrophy (OR, 5.46; 95% CI, 1.71–17.45), and severe leukoaraiosis (OR,
64	4.68; 95% CI, 1.93–11.31). However, brain frailty was not significantly associated with AIS
65	complications (malignant cerebral edema, parenchymal hemorrhage). Including brain atrophy
66	indicators in the model significantly improved its unfavorable clinical outcome predictive
67	power (AUC increased from 0.762 to 0.822; $p < 0.001$). The results remained stable in
68	subgroup analyses across treatment modalities.
69	CONCLUSIONS: Brain frailty was significantly associated with the unfavorable clinical
70	outcome but not with acute complications. Brain frailty indicators contributed to the
71	predictive efficacy, regardless of treatment modality.

73 Key Words:

74 atrophy; cerebral edema; frailty; ischemic stroke; leukoaraiosis; prognosis

75

76 Non-standard Abbreviations and Acronyms

- 77 AIS, acute ischemic stroke
- 78 AUC, area under the receiver operating characteristic curve
- 79 CDFs, cumulative distribution functions
- 80 DWI, diffusion-weighted imaging
- 81 FLAIR, fluid-enhanced inversion recovery
- 82 mRS, modified Rankin Scale
- 83 NIHSS, National Institutes of Health Stroke Scale
- 84 ROC, receptor operating characteristic

85 T1WI, T1-weighted imaging

86 T2WI, T2-weighted imaging

87

88 INTRODUCTION

Frailty is a clinically recognizable state of reduced physiological reserves in which older 89 adults are more likely to experience a state of poor homeostasis resolution after a stressful 90 event, increasing the risk of adverse outcomes.^{1, 2} Acute ischemic stroke (AIS) represents a 91 quintessential stressor event, with up to 28% of patients with stroke having pre-existing 92 frailty on hospital admission.³ The analysis of data from 483.033 participants in the UK 93 Biobank revealed an association between physical frailty and health-related outcomes, which 94 could be mediated by differences in brain structure.⁴ These differences are primarily 95 characterized by hyperintensity on MRI and lower subcortical grey matter volume.⁴ These 96 brain frailty indicators facilitate a more objective assessment than physical signs of frailty. 97

Evidence suggests indicators of brain frailty are important for stroke prognosis. Post hoc 98 analyses of randomized controlled trials showed that CT-assessed indicators of brain frailty 99 were associated with decreased functional independence in patients with AIS who received 100 intravenous thrombolysis⁵ or endovascular therapy⁶. However, studies using MRI-assessed 101 indicators of cerebral small-vessel disease, such as lacunes, enlarged perivascular spaces, and 102 white matter hyperintensities, indicated that they are not associated with functional 103 outcomes.^{7,8} Therefore, the choice of indicators might affect findings when assessing the 104 relationship between brain atrophy and prognosis. Furthermore, it is unknown whether brain 105 106 frailty has a differential effect on acute complications and functional outcome at 90 days. Various factors influence AIS prognosis. Commonly used indicators to assess stroke 107 complications and functional prognosis include age, National Institutes of Health Stroke 108 Scale (NIHSS) score, infarct volume, blood glucose, and comorbidities.⁹⁻¹¹ Clinicians 109 combine multiple variables in their clinical decision-making process when treating individual 110 patients. However, few studies have used indicators of brain frailty as an important 111 component in predicting outcomes. Moreover, whether brain frailty enhances models' 112 predictive power remains unknown. 113

This multicenter, retrospective study analyzed real-world patients with AIS caused by 114 anterior circulation large-vessel occlusion who received various treatment modalities. The 115 selected indicators of brain frailty included subcortical and cortical atrophy and leukoaraiosis, 116 117 which can be obtained by simple measurements on CT and MRI scans and are suitable for use in prospective clinical applications. This study aimed to 1) assess the association between 118 brain frailty indicators and AIS complications (malignant cerebral edema, parenchymal 119 hemorrhage) and unfavorable functional outcomes at 90 days and 2) assess the ability of 120 brain frailty indicators to predict outcomes and increase predictive efficacy. 121

122

123 METHODS

This study was approved by the local ethics committees of all participating institutions
(2024DZKY-019-01). The requirement for informed consent was waived by the local ethics
committees. We followed the Standards for the Reporting of Diagnostic Accuracy Studies
(STARD) guidelines for study execution and reporting (Supplemental Material). Data
underpinning the findings of this study can be obtained from the corresponding author upon a
reasonable request.

130

131 Study population

132 This multicenter, retrospective, observational cohort study used data from five centers. We

133 considered consecutive patients presenting with AIS due to large-vessel occlusion in the

anterior circulation treated between May 2018 and June 2023. The inclusion criteria were (1)

adult patients (aged ≥ 18 years); (2) underwent MRI within seven days of admission; (3)

136 presence of anterior circulation vessel occlusion (internal carotid or middle cerebral artery

137 M1 or M2); (4) the 90-day modified Rankin Scale (mRS) score was not missing. Patients

138 were excluded if they underwent the MRI beyond seven days or had an intracranial tumor,

AIS in the posterior circulation or anterior cerebral artery supply area, severe artifacts,

140 considerable midline shift, and segmentation failure that made it impossible to measure the

- 141 infarct volume.
- 142

143 Clinical assessment and outcomes

We retrieved demographic, clinical, laboratory, and imaging data from the electronic medicalrecord, including information on the patient's age and sex, comorbidities such as

146 hypertension and diabetes mellitus, history of atrial fibrillation and stroke, and the NIHSS

score at admission. Laboratory values included blood glucose, glycated hemoglobin, 147 low-density lipoprotein, high-density lipoprotein, and total cholesterol on admission. 148 The primary outcome was the 90-day functional outcome, assessed using the mRS, 149 obtained by clinical follow-up or a telephone call. The mRS is an ordinal scale used to 150 measure the degree of disability in daily activities. It ranges from 0 (no symptoms) to 6 151 (death).¹² An mRS of 3 to 6 was defined as an unfavorable clinical outcome. The secondary 152 outcomes were malignant cerebral edema and parenchymal hemorrhage. Malignant cerebral 153 edema was defined as a large occupying infarct in the middle cerebral artery compressing the 154 155 ventricles or causing midline shift of ≥ 5 mm, consciousness level of ≥ 1 on item 1a of the NIHSS, and no other causes of neurological deterioration.¹³ Parenchymal hemorrhage was 156 determined based on follow-up imaging and following the European Cooperative Acute 157 Stroke Study II criteria.¹⁴ 158

159

160 **Image acquisition**

161 MRI scans are part of routine clinical care. Since data were collected retrospectively from

several clinical facilities, we could not ensure uniform scanner type, scanned area, and

scanning protocol. Images were acquired using a 1.5-T or 3-T scanner (GE Discovery

164 MR750 3T, Philips Ingenia 3T, Siemens Skyra 3T or Siemens Avanto 1.5T). The scanning

sequences included T2-weighted imaging (T2WI), T1-weighted imaging (T1WI),

166 fluid-enhanced inversion recovery (FLAIR), and diffusion-weighted imaging (DWI)

sequences. The parameters of MRI acquisition were detailed in Supplementary Table S1.

168

169 Image analysis

170 Brain frailty assessment

Brain frailty (subcortical and cortical atrophy and leukoaraiosis) was assessed on T1WI,
T2WI, or FLAIR sequence. The assessment included the contralateral cerebral hemisphere to
avoid confusion due to the acute stroke.

Subcortical atrophy was measured by a senior radiologist with 15 years of experience (***) who were blinded to the clinical information. Subcortical atrophy was assessed by calculating the ratio between the inter-caudate distance and the inner table width.^{15,16} The inter-caudate distance was defined as the minimum distance between the head of the caudate nucleus and the septum lucidum at the level of the foramen of Monroe, multiplied by 2. The distance was measured in the contralateral hemisphere to avoid errors due to infarct-related edema.

Cortical atrophy and leukoaraiosis were assessed by two radiologists with six years of 181 neuroimaging experience (** and ***) who were blinded to the clinical information. 182 Disagreements were resolved by a senior radiologist with fifteen years of experience (***). 183 Cortical atrophy was assessed using the global cortical atrophy scale, which evaluates the 184 degree of cortical atrophy by assessing the sulcus's width and the gyrus's volume. The scale 185 ranges from 0 (no atrophy) to 3 (severe atrophy).¹⁷ Leukoaraiosis was visually assessed for 186 periventricular and deep white matter lesions and a 3-level scale was used to classify 187 whole-brain leukoaraiosis: none or mild (score 0-1), moderate (score 2), and severe (score 188 3) ^{18,19} 189

190

191 Infarct volume assessment

An acute infarct segmentation model was established based on the VB-Net structure to automatically segment the whole lesion area on DWI with a b-value of 1,000 s/mm² and with apparent diffusion coefficient map reconstruction images. The automatic segmentation sequence was as follows: 1) Extract the brain tissue from the DWI image to reduce the

interference caused by the skull and other parts of the image; 2) normalize the extracted brain
tissue so that the image grey scale range will be [0, 1]; 3) use the pre-processed image above
as the input to the cascade neural network, and perform step-by-step coarse and fine
segmentation of the DWI brain image; 4) obtain the lesion segmentation results based on
voxel analysis. Two neuroradiologists with six years of neuroimaging experience proofread
the automatic segmentation results (** and ***).

202

203 Statistical analysis

204 Categorical variables are presented as counts (percentages) and were compared using the χ^2

test. Continuous variables are presented as median (interquartile range, IQR) or mean

206 (standard deviation, SD) based on their distribution, evaluated with the Shapiro-Wilk test,

and compared using the Mann-Whitney U test or *t*-test, as appropriate.


Multivariate logistic regression, adjusted for age, sex, NIHSS score, and infarct volume, 208 helped determine whether brain frailty was associated with acute complications and 209 unfavorable 90-day clinical outcomes. We also performed subgroup analysis after dividing 210 the patients based on the treatment modality received. The area under the receiver operating 211 characteristic (ROC) curve (AUC) was used to assess the ability of individual variables at 212 baseline, including the NIHSS score, infarct volume, baseline glucose, and subcortical 213 atrophy, to predict unfavorable clinical outcomes. The AUC was combined with the 214 215 multivariate variables to assess whether the brain atrophy indicators could predict unfavorable clinical outcome with a significant potentiating effect. The DeLong test 216 compared the AUC of various variables. Statistical significance was set at p < 0.05. 217 218 Statistical analysis was performed using R (https://www.r-project.org; The R Foundation) and EmpowerStats (https://www.empowerstats.com;X&Y Solutions, Inc). 219

220

221 **RESULTS**

222 Baseline patient characteristics

- Among the 1,337 consecutively included patients with AIS due to acute large-vessel
- occlusion in the anterior circulation, 247 were considered ineligible (Figure 1): the MRI
- examination was performed more than seven days after admission in 92 patients; 5 patients
- had brain tumors; 39 patients had regional strokes in the vertebral basilar, posterior cerebral,
- or anterior cerebral artery; 24 patients had severe artifacts; 45 patients were missing the
- T1WI sequence; 11 patients had extensive midline shift; DWI volume calculation failed in 31
- 229 patients.



230

231

Figure 1. Patient selection flowchart.

- Abbreviation: CC/IT, intercaudate distance to inner table width;GCA, global cortical atrophy score
- 233

```
The median age of the remaining 1,090 participants was 64 (IQR, 55–73) years, and 754
```

- 235 (69.2%) were male. Endovascular treatment was given to 443 patients (40.6%), intravenous
- thrombolysis to 143 (13.1%), and medical therapy to 504 (46.3%). The median NIHSS score
- 237 was 9 (IQR, 4.50–14.00), and the median infarct volume was 13.42 (IQR, 4.33–44.45) mL.

Parenchymal hemorrhage was detected in 122 patients (11.2%), malignant cerebral edema in
42 (3.9%), and unfavorable 90-day clinical outcomes in 435 (39.9%).

240	A comparison of the data for patients with favorable and unfavorable clinical outcomes
241	is shown in Table 1. Patients with unfavorable clinical outcomes had higher median age [67
242	(IQR, 58–75) vs. 62 (IQR, 52–70) years; $p < 0.001$], NIHSS score [13 (IQR, 8–17) vs. 7
243	(IQR, 3–12); <i>p</i> < 0.001], and infarct volume [26.08 (IQR, 7.44–101.13) vs. 10.12 (IQR, 3.51–
244	26.37) mL; $p < 0.001$] than patients with favorable clinical outcomes. For brain atrophy
245	indicators, patients with unfavorable clinical outcomes had more severe median subcortical
246	atrophy [0.13 (IQR, 0.11–0.15) vs. 0.11 (IQR, 0.09–0.13); <i>P</i> < 0.001], severe cortical atrophy
247	rate (8.51% vs. 1.98% ; $p < 0.001$), and Fazekas scores of 3 (12.64% vs. 3.97% ; $p < 0.001$)
248	than those with favorable clinical outcomes.

 Table 1. Clinical and imaging characteristics of the patient population

Characteristic	All participants (n = 1090)	Favorable outcome (mRS 0–2, n = 655)	Unfavorable outcome (mRS 3–6, n = 435)	<i>P</i> -value	
Age, y, median (IQR)	64.00 (55.00-73.00)	62.00 (52.00-70.00)	67.00 (58.00-75.00)	< 0.001	
Sex, male, n (%)	754 (69.2%)	479 (73.1%)	275 (63.2%)	< 0.001	
Baseline NIHSS, median (IQR)	9.00 (4.50-14.00)	7.00 (3.00-12.00)	13.00 (8.00-17.00)	< 0.001	
Infarction volume, median (IQR), mL	13.42 (4.33-44.45)	10.12 (3.51-26.37)	26.08 (7.44-101.13)	< 0.001	
Laboratory data	·	·			
Blood glucose, median (IQR), mmol/L	5.73 (4.88-7.33)	5.40 (4.70-7.00)	6.40 (5.18-8.08)	< 0.001	
HbA1c, median (IQR), %	5.90 (5.50-6.90)	5.80 (5.45-7.00)	5.90 (5.50-6.80)	0.442	
Total cholesterol, median (IQR), mmol/L	4.24 (3.62-4.98)	4.21 (3.62-5.01)	4.29 (3.62-4.91)	0.587	
LDL, median (IQR), mmol/L	2.48 (1.93-3.14)	2.48 (1.94-3.13)	2.50 (1.92-3.16)	0.316	
HDL, median (IQR), mmol/L	1.04 (0.88-1.24)	1.03 (0.87-1.23)	1.04 (0.89-1.27)	0.581	
Brain frailty	·	·			
CC/IT ratio, median (IQR)	0.12 (0.10-0.14)	0.11 (0.09-0.13)	0.13 (0.11-0.15)	< 0.001	
Global cortical atrophy score				< 0.001	
0-1	754 (69.2%)	516 (78.8%)	238 (54.7%)		
2	286 (26.2%)	126 (19.2%)	160 (36.8%)		
3	50 (4.6%)	13 (2.0%)	37 (8.5%)		
Fazekas score				< 0.001	
0-1	706 (64.8%)	488 (74.5%)	218 (50.1%)	1	
2	303 (27.8%)	141 (21.5%)	162 (37.2%)	1	
3	81 (7.4%)	26 (4.0%)	55 (12.6%)		

Comorbidities								
Hypertension, n (%) 688 (63.2%) 409 (62.4%) 279 (64.3%)								
Diabetes, n (%)	229 (21.0%)	136 (20.8%)	93 (21.4%)	0.792				
Atrial fibrillation, n (%)	166 (15.3%)	81 (12.4%)	85 (19.6%)	0.001				
Previous stroke, n (%)	62 (5.7%)	33 (5.0%) 29 (6.7%)		0.256				
Treatment				< 0.001				
Medical therapy, n (%)	Medical therapy, n (%) 504 (46.2%) 342 (52.2%) 162 (37.2%)							
Endovascular therapy, n (%)	443 (40.6%)	250 (38.2%)	193 (44.4%)					
Intravenous thrombolysis, n (%)	ntravenous thrombolysis, n (%) 143 (13.1%) 63 (9.6%) 80 (18.4%)							

250 Abbreviations: CC/IT, intercaudate distance to inner table width; IQR, 25th–75th percentile; LDL, low-density

lipoprotein; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; HbA1c, glycated
 hemoglobin; HDL, high-density lipoprotein

253

254 Association of brain frailty with complications and outcomes

255 Multivariate logistic regression models adjusted for age, sex, NIHSS score, and infarct

volume are shown in Table 2. For malignant cerebral edema, NIHSS score (OR, 1.13; 95%

257 CI, 1.07–1.20; *p* < 0.001), blood glucose (OR, 1.30; 95% CI, 1.12–1.51; *p* < 0.001), and

infarct volume (OR, 1.67; 95% CI, 1.24–2.25; p < 0.001) were independent risk factors,

while subcortical atrophy, cortical atrophy, and leukoaraiosis were not (Table 2). For

parenchymal hemorrhage, NIHSS score (OR, 1.08; 95% CI, 1.03–1.12; p < 0.001) and infarct

volume (OR, 1.67; 95% CI, 1.38–2.02; p < 0.001) were independent risk factors, whereas

none of the remaining variables were significantly associated (Table 2).

For unfavorable clinical outcomes, NIHSS score (OR, 1.17; 95% CI, 1.13–1.22; p < p

264 0.001), blood glucose (OR, 1.15; 95% CI, 1.04–1.26; *p* = 0.005), infarct volume (OR, 1.32;

265 95% CI, 1.15–1.52; *p* = 0.001), subcortical atrophy (OR, 1.27; 95% CI, 1.18–1.37; *p* < 0.001),

severe cortical atrophy (OR, 5.46; 95% CI, 1.71-17.45, p = 0.004), and Fazekas score of 3

267 (OR, 4.68; 95% CI, 1.93–11.31; p = 0.001) were independent predictors of unfavorable

268 clinical outcomes.

269

270 Table 2. Multivariate logistic regression models for complications and unfavorable outcomes

All rights reserved.	No reuse allowed without permission.	
All fights reserved.	No reuse allowed without permission.	

Variable	Malignant cerebral edema		Parenchymal her	morrhage	Unfavorable outcome		
Variable	OR (95% CI)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value	
Age, y	1.01 (0.97, 1.05)	0.624	1.02 (0.99, 1.05)	0.121	0.99 (0.97, 1.00)	0.078	
Sex, male	1.18 (0.48, 2.85)	0.720	0.96 (0.55, 1.69)	0.895	0.48 (0.30, 0.76)	0.002	
Baseline NIHSS	1.13 (1.07, 1.20)	< 0.001	1.08 (1.03, 1.12)	< 0.001	1.17 (1.13, 1.22)	< 0.001	
Infarction volume	1.67 (1.24, 2.25)	< 0.001	1.67 (1.38, 2.02)	< 0.001	1.32 (1.15, 1.52)	0.001	
Blood glucose	1.30 (1.12, 1.51)	< 0.001	1.06 (0.95, 1.18)	0.312	1.15 (1.04, 1.26)	0.005	
CC/IT ratio	0.60 (0.15, 2.32)	0.457	1.02 (0.42, 2.46)	0.969	1.27 (1.18, 1.37)	< 0.001	
Global cortical atrophy							
0-1	Reference		Reference		Reference		
2	0.64 (0.23, 1.78)	0.394	1.02 (0.53, 1.96)	0.963	2.28 (1.36, 3.83)	0.002	
3	0.75 (0.08, 7.07)	0.805	1.51 (0.46, 5.00)	0.501	5.46 (1.71, 17.45)	0.004	
Fazekas score							
0-1	1 Reference		Reference		Reference		
2	0.81 (0.28, 2.33)	0.701	0.63 (0.32, 1.22)	0.173	2.09 (1.30, 3.35)	0.002	
3	0.87 (0.17, 4.53)	0.868	1.04 (0.38, 2.87)	0.936	4.68 (1.93, 11.31)	0.001	

271

Abbreviations: CC/IT, intercaudate distance to inner table width; mRS, modified Rankin Scale; NIHSS,

272 National Institutes of Health Stroke Scale. Adjusted for age, sex, NIHSS score, and infarct volume.

273

274 The cumulative distribution functions (CDFs) of brain frailty indicators associated with

adverse clinical outcomes are shown in Figure 2. The CDFs illustrate that the cumulative

276 probability of unfavorable clinical outcomes increases with the severity of subcortical

atrophy (Figure 2A), cortical atrophy (Figure 2B), and leukoaraiosis (Figure 2C). The

distribution of 90-day mRS scores for indicators of brain frailty is shown in Figure 3.





Figure 2. Cumulative distribution functions (CDFs) of brain frailty indicators with unfavorable 281 clinical outcome (modified Rankin scale score 3-6). A-C In all patients with acute ischaemic stroke, the 282 283 CDFs illustrate that the cumulative probability of unfavorable clinical outcomes increases with the severity of 284 subcortical atrophy(CC/IT radio) (A), cortical atrophy (global cortical atrophy score) (B), and leukoaraiosis 285 (Fazakes score)(C). D-F Subgroup analysis of different treatments to assess the cumulative probability 286 distribution of subcortical atrophy (D), cortical atrophy (E) and leukoaraiosis (F) with unfavorable clinical 287 outcome. Abbreviation: CC/IT, intercaudate distance to inner table width.



288

289 Figure 3. Distribution of 90-day mRS score for each indicator of brain frailty.

A Distribution of 90-day mRS scores for subcortical atrophy (CC/IT ratio trisection); B Distribution of 90-day
 mRS scores for cortical atrophy (3-level score); C Distribution of 90-day mRS scores for leukoaraiosis (Fazekas
 score). Abbreviations: CC/IT, intercaudate distance to inner table width; mRS, modified Rankin Scale.

293

294 **ROC** analysis for unfavorable clinical outcome

295 Univariable ROC analysis determined the AUCs for subcortical atrophy (0.655; 95% CI,

296 0.622–0.688), infarct volume (0.665; 95% CI, 0.632–0.699), blood glucose (0.623; 95% CI,

297 0.586–0.660), and NIHSS score (0.724; 95% CI, 0.694–0.754) (Supplementary Table S2).

298 The diagnostic power of the NIHSS score was statistically better than that of infarct volume

(DeLong test; p = 0.002) and subcortical atrophy (p = 0.003); infarct volume and subcortical

atrophy had comparable predictive efficacy for unfavorable clinical outcomes (p = 0.609).

The unfavorable clinical outcome prediction model (model 1) developed with age, sex,

302 NIHSS score, blood glucose, and infarct volume showed discriminatory power with an AUC

303 of 0.762 (95% CI, 0.731–0.793), sensitivity of 64.0%, and specificity of 75.9%. The AUC of

the model 1 increased significantly when brain atrophy indicators were included (Model 2;

305 0.822; 95% CI, 0.796–0.849; DeLong test; p < 0.001; Figure 4).





Figure 4. Receiver operating characteristic curves for predicting unfavorable clinical outcomes.

Model 1: Age + Sex + NIHSS + Blood glucose + Infarction volume; Model 2: Model 1 + CC/IT ratio + GCA + Fazekas scores. Abbreviations: CC/IT, intercaudate distance to inner table width; GCA, global cortical atrophy score; NIHSS, National Institutes of Health Stroke Scale.

Subgroup analysis was conducted by treatment type, showing an increase in the AUC
from Model 1 to Model 2 in all. For patients receiving endovascular treatment, the AUCs of
Models 1 and 2 were 0.740 (95% CI, 0.686–0.793) and 0.872 (95% CI, 0.835–0.909),
respectively. The respective AUCs for patients receiving medical therapy were 0.756 (95%
CI, 0.710–0.802) and 0.812 (95% CI, 0.772–0.852). The respective AUCs for patients
receiving intravenous thrombolysis were 0.849(95% CI, 0.781–0.917) and 0.888 (95% CI,
0.826–0.950) (Figure 5).



327

Figure 5. Receiver operating characteristic curves predicting unfavourable clinical outcomes (stratified analysis of treatment modalities).

330 Model 1: Age+Sex+NIHSS+Blood glucose + Infarction volume; Model 2: Model 1+CC/IT ratio+GCA+Fazekas

331 scores. Abbreviations: CC/IT, intercaudate distance to inner table width; GCA,global cortical atrophy score;

332 mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.

333

334 **DISCUSSION**

- This multicenter study identified 1,090 patients with AIS due to large-vessel occlusion of the
- anterior circulation and assessed the impact of brain atrophy indicators on acute
- complications and 90-day clinical outcomes. First, we confirm the prognostic values of
- subcortical atrophy, cortical atrophy, and leukoaraiosis, which were independently associated

with unfavorable clinical outcomes. Second, quantitative measures of subcortical atrophy 339 were comparable to infarct volume in predicting unfavorable clinical outcomes, and inclusion 340 of brain atrophy indicators significantly improved the predictive power of the multivariate 341 logistic regression models. In addition, no correlation was found between malignant cerebral 342 edema or parenchymal hemorrhage secondary to AIS and brain atrophy. The results of this 343 study highlight the importance of integrating brain atrophy into the clinical diagnostic 344 predictions and therapeutic decision-making for patients with AIS and help understand the 345 differential impact brain atrophy has on acute complications and long-term prognosis of 346 347 stroke.

Brain atrophy reflects the resilience or vulnerability of the brain due to the accumulation 348 of multiple chronic damages.²⁰ The present study confirmed the important prognostic value 349 of cortical atrophy, subcortical atrophy, and leukoaraiosis, each independently associated 350 with unfavorable clinical outcomes. The ESCAPE-NA1 trial included patients with 351 endovascular thrombolysis. Patients with cortical and subcortical atrophy detected by visual 352 assessment of acute CT images had a less favorable AIS recovery and worse 90-day 353 functional prognosis than patients without brain atrophy.⁶ A secondary analysis of that trial 354 found that 85.1% of the association between age and 90-day functional outcomes after 355 thrombectomy was mediated by brain frailty features, highlighting the importance of brain 356 atrophy rather than chronological age alone in predicting stroke prognosis.¹⁶ In the 357 358 International Stroke Trial (IST-3), which included patients with ischemic stroke who underwent intravenous thrombolysis, pre-existing brain CT signs (old infarcts, leukoaraiosis, 359 and atrophy) were associated with decreased functional independence and increased 360 symptomatic intracranial hemorrhage.⁵ The findings of our study, which included real-world 361 patients with AIS receiving various treatment modalities, are consistent with the results 362 described above, further demonstrating the importance of brain atrophy indicators for stroke 363

prognosis. Furthermore, the brain atrophy indicators chosen for this study took into account clinical feasibility and reproducibility and are easily detectable on CT or MRI scans.¹⁵ The simple quantitative measurement of subcortical atrophy avoids the influence of the infarcted side of the brain, and visual assessment of cortical atrophy and leukoaraiosis is easy to perform without relying on any special software.

The prognostic predictive power of the model based on the remaining predictors of 369 complications and unfavorable clinical outcomes found in our study, including age, NIHSS 370 score, infarct volume, and blood glucose, improved significantly when combined with brain 371 372 frailty indicators. Prognostic prediction models used in other studies relied on various variable combinations. For example, the THRIVE score included age, initial NIHSS score, 373 and comorbidities.⁹ The SPAN-100 index summed the patient's age and NIHSS score to 374 predict clinical outcomes after intravenous and mechanical thrombolysis.¹¹ The PRE score 375 model combined the patient's age, initial NIHSS score, and the Alberta Stroke Program Early 376 Computed Tomography Score (ASPECTS) as continuous variables.¹⁰ The MRI-DRAGON 377 score, which includes clinical (age, NIHSS score, glucose level, pre-stroke disability, and 378 onset-to-treatment time) and radiological (DWI-ASPECTS, M1 occlusion) variables, had a 379 high specificity for predicting the prognosis.²¹ None of these models included indicators of 380 brain atrophy, and regardless of their complexity, their discriminative performance ranged 381 between 0.73 and 0.83.^{9,10,11,21} A recent study showed that adding cortical atrophy and 382 383 age-related white matter changes led to a small but significant improvement in machine learning-based clinical outcome prediction models, increasing the AUC from 0.763 to 384 0.775.²² The present study used conventional variables and traditional logistic regression 385 methods, achieving a significant increase in the AUC for predicting unfavorable clinical 386 outcomes from 0.762 to 0.822 (p < 0.001) when including the brain atrophy indicators. The 387 results remained stable in the treatment modality-based subgroup analyses. 388

Interesting differences in the correlation of brain atrophy with acute complications and 389 functional recovery at 90 days were noted. The idea that brain atrophy might act as a buffer 390 against acute stroke-induced brain swelling and occupancy effects has been previously 391 suggested.^{23,24} A recent study investigated the effect of brain atrophy on the outcomes after 392 endovascular treatment in 295 patients with AIS using visual scores and the Evans index (the 393 ratio between the maximum widths of the frontal horns of the lateral ventricles and the 394 395 maximal internal diameter of the skull at the same level). They found a positive association between the risk of futile reperfusion and atrophy; however, the Evans index does not 396 account for underlying AIS-related edema or hemorrhage.²³ A post hoc analysis of the 397 ENCHANTED trial showed that brain atrophy was associated with lower early mortality in 398 patients with stroke, possibly because brain atrophy made them more tolerant to brain 399 swelling; however, the loss of neuronal plasticity and recovery also led to poorer functional 400 prognosis.²⁴ In our study, brain atrophy indicators did not significantly correlate with 401 malignant brain edema or parenchymal hemorrhage, while the same indicators were risk 402 factors for unfavorable 90-day functional outcomes. This difference indirectly reflects the 403 different mechanisms through which brain atrophy affects acute complications and long-term 404 prognosis. Clinical treatment decisions should take this difference into account. 405 The strengths of our study include the stability of the correlation between brain frailty 406 and prognosis across various treatment modalities, and the difference between acute 407 408 complications and 90-day prognosis in their correlation with brain frailty indicators. Moreover, the brain frailty indicators selected for this study are easy to measure and suitable 409 for use in acute stroke settings and prospective studies. This study had some limitations: 1. 410 Lack of finer segmentation and measurement of cortical and subcortical atrophy. In the 411 absence of quantitative measurements of the leukoaraiosis volume, we used the Fazekas scale. 412 2. Some indicators of cerebral small vessel disease, such as microhemorrhages, lacunae, and 413

enlarged perivascular spaces, were not assessed, given the commonality of the indicators 414 between CT and MRI assessments. 3. The small number of patients receiving IV 415 thrombolysis may have biased the study finding. 4. The model in this study obtained the 416 prediction results for unfavorable clinical outcome through multivariate logistic regression 417 analysis; because of the lack of cross-validation, it is possible that the results of the model are 418 overly optimistic. 419 In conclusion, the present study suggests that brain frailty indices are strong independent 420 prognostic predictors of AIS due to large-vessel occlusion; however, they are not associated 421 422 with acute complications. These findings have important implications for guiding patients' acute treatment and functional recovery. Brain frailty indicators significantly enhanced the 423 prediction of patient prognosis. The selection of simple, easy-to-measure indicators of brain 424 frailty that can be easily integrated into existing predictive models could support prospective 425 therapeutic decision-making. 426 427 Acknowledgments 428 None 429 430 **Sources of Funding** 431 This research was funded by the National Natural Scientific Foundation of China 432 433 (82271983). 434 Disclosures 435 All authors have read and approved the submitted manuscript, the manuscript has not been 436 submitted elsewhere nor published elsewhere in whole or in part. There are no any ethical or 437 legal conflicts involved in this manuscript. 438

439 **References**

- 1. Evans NR, Todd OM, Minhas JS, Fearon P, Harston GW, Mant J, Mead G, Hewitt J, Quinn TJ,
- 441 Warburton EA. Frailty and cerebrovascular disease: Concepts and clinical implications for stroke
- 442 medicine. Int J Stroke. 2022 ;17:251-259. doi: 10.1177/17474930211034331
- 443 2. Kim DH, Rockwood K. Frailty in Older Adults. N Engl J Med. 2024;391:538-548. doi:
- 444 10.1056/NEJMra2301292. PMID: 39115063.
- 3. Taylor-Rowan M, Hafdi M, Drozdowska B, Elliott E, Wardlaw J, Quinn TJ. Physical and brain
- frailty in ischaemic stroke or TIA: Shared occurrence and outcomes. A cohort study. Eur Stroke J.
- 447 2023 ;8:1011-1020. doi: 10.1177/23969873231186480
- 448 4. Jiang R, Noble S, Sui J, Yoo K, Rosenblatt M, Horien C, Qi S, Liang Q, Sun H, Calhoun VD, et al.
- Associations of physical frailty with health outcomes and brain structure in 483 033 middle-aged
- 450 and older adults: a population-based study from the UK Biobank. Lancet Digit Health.
- 451 2023;5:e350-e359. doi: 10.1016/S2589-7500(23)00043-2
- 452 5. IST-3 collaborative group. Association between brain imaging signs, early and late outcomes, and
- 453 response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial
- 454 (IST-3): secondary analysis of a randomised controlled trial. Lancet Neurol. 2015 ;14:485-96. doi:
- 455 10.1016/S1474-4422(15)00012-5
- 456 6. Benali F, Fladt J, Jaroenngarmsamer T, Bala F, Singh N, Ospel JM, Tymianski M, Hill MD, Goyal
- 457 M, Ganesh A. Association of Brain Atrophy With Functional Outcome and Recovery Trajectories
- 458 After Thrombectomy: Post Hoc Analysis of the ESCAPE-NA1 Trial. Neurology.

459 2023 ;101:e1521-e1530. doi: 10.1212/WNL.000000000207700

- 460 7. Bu N, Khlif MS, Lemmens R, Wouters A, Fiebach JB, Chamorro A, Ringelstein EB, Norrving B,
- 461 Laage R, Grond M, et al. Imaging Markers of Brain Frailty and Outcome in Patients With Acute
- 462 Ischemic Stroke. Stroke. 2021;52:1004-1011. doi: 10.1161/STROKEAHA.120.029841
- 463 8. Arba F, Inzitari D, Ali M, Warach SJ, Luby M, Lees KR; STIR/VISTA Imaging Collaboration.
- 464 Small vessel disease and clinical outcomes after IV rt-PA treatment. Acta Neurol Scand.
- **465** 2017;136:72-77. doi: 10.1111/ane.12745


- 466 9. Flint AC, Rao VA, Chan SL, Cullen SP, Faigeles BS, Smith WS, Bath PM, Wahlgren N, Ahmed N,
- 467 Donnan GA, et al. Improved ischemic stroke outcome prediction using model estimation of
- 468 outcome probability: the THRIVE-c calculation. Int J Stroke. 2015;10:815-21. doi:
- 469 10.1111/ijs.12529
- 470 10. angaraju S, Aghaebrahim A, Streib C, Sun CH, Ribo M, Muchada M, Nogueira R, Frankel M,
- 471 Gupta R, Jadhav A, et al. Pittsburgh Response to Endovascular therapy (PRE) score: optimizing
- 472 patient selection for endovascular therapy for large vessel occlusion strokes. J Neurointerv Surg.
- 473 2015;7:783-8. doi: 10.1136/neurintsurg-2014-011351
- 11. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke Prognostication using Age
- and NIH Stroke Scale: SPAN-100. Neurology. 2013 ;80:21-8. doi:
- 476 10.1212/WNL.0b013e31827b1ace
- 477 12. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for
 478 the assessment of handicap in stroke patients. Stroke.1988;19:604-7. doi: 10.1161/01.str.19.5.604
- 13. Irvine HJ, Ostwaldt AC, Bevers MB, Dixon S, Battey TW, Campbell BC, Davis SM, Donnan GA,
- 480 Sheth KN, Jahan R, et al. Reperfusion after ischemic stroke is associated with reduced brain edema.
- 481 J Cereb Blood Flow Metab. 2018;38:1807-1817. doi: 10.1177/0271678X17720559
- 482 14. Larrue V, von Kummer R R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic
- 483 transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a
- 484 secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke.
- 485 2001;32:438-41. doi: 10.1161/01.str.32.2.438
- 486 15. Jaroenngarmsamer T, Benali F, Fladt J, Singh N, Bala F, Tymianski M, Hill MD, Goyal M, Ganesh
- 487 A; ESCAPE-NA1 Investigators. Cortical and Subcortical Brain Atrophy Assessment Using
- 488 Simple Measures on NCCT Compared with MRI in Acute Stroke. AJNR Am J Neuroradiol.
- **489** 2023;44:1144-1149.doi: 10.3174/ajnr.A7981
- 16. Benali F, Singh N, Fladt J, Jaroenngarmsamer T, Bala F, Ospel JM, Buck BH, Dowlatshahi D,
- 491 Field TS, Hanel RA, et al. Mediation of Age and Thrombectomy Outcome by Neuroimaging
- 492 Markers of Frailty in Patients With Stroke. JAMA Netw Open. 2024 ;7:e2349628. doi:
- 493 10.1001/jamanetworkopen.2023.49628


- 494 17. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver
- reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol.
 1996;36:268-72. doi: 10.1159/000117270
- 497 18. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in
- 498 Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-6. doi:
- 499 10.2214/ajr.149.2.351
- 500 19. Oveisgharan S, Yu L, Poole VN, Evia AM, Barnes LL, Schneider JA, Arfanakis K, Bennett DA,
- 501 Buchman AS. Association of White Matter Hyperintensities With Pathology and Progression of
- 502 Parkinsonism in Aging. JAMA Neurol. 2021 ;78:1494-1502. doi: 10.1001/jamaneurol.2021.3996
- 20. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity
- and implications for health care, research, and medical education: a cross-sectional study. Lancet.
- **505** 2012;380:37-43. doi: 10.1016/S0140-6736(12)60240-2
- 506 21. Ben Hassen W, Raynaud N, Bricout N, Boulouis G, Legrand L, Ferrigno M, Kazemi A, Bretzner M,
- 507 Soize S, Farhat W, et al. MT-DRAGON score for outcome prediction in acute ischemic stroke
- treated by mechanical thrombectomy within 8 hours. J Neurointerv Surg. 2020;12:246-251. doi:
- 509 10.1136/neurintsurg-2019-015105
- 510 22. Brugnara G, Engel A, Jesser J, Ringleb PA, Purrucker J, Möhlenbruch MA, Bendszus M,
- 511 Neuberger U. Cortical atrophy on baseline computed tomography imaging predicts clinical
- 512 outcome in patients undergoing endovascular treatment for acute ischemic stroke. Eur Radiol.
- 513 2024;34:1358-1366. doi: 10.1007/s00330-023-10107-2
- 514 23. Pedraza MI, de Lera M, Bos D, Calleja AI, Cortijo E, Gómez-Vicente B, Reyes J, Coco-Martín MB,
- 515 Calonge T, Agulla J, et al. Brain Atrophy and the Risk of Futile Endovascular Reperfusion in Acute
- 516 Ischemic Stroke. Stroke. 2020;51:1514-1521. doi: 10.1161/STROKEAHA.119.028511
- 517 24. Delcourt C, Wang X, Zhou Z, Wardlaw JM, Mair G, Robinson TG, Chen X, Yoshimura S,
- 518 Torii-Yoshimura T, Carcel C, et al. Brain imaging abnormalities and outcome after acute ischaemic
- stroke: the ENCHANTED trial. J Neurol Neurosurg Psychiatry. 2020;91:1290-1296. doi:
- **520** 10.1136/jnnp-2020-323015


521 Figure legends


522

- 523 Figure 1. Patient selection flowchart.
- 524 Figure 2. Cumulative distribution functions (CDFs) of brain frailty indicators with
- unfavorable clinical outcome (modified Rankin scale score 3–6).
- 526 Figure 3. Distribution of 90-day mRS score for each indicator of brain frailty.
- Figure 4. Receiver operating characteristic curves for predicting unfavorable clinicaloutcomes.
- 529 Figure 5. Receiver operating characteristic curves predicting unfavourable clinical outcomes
- 530 (stratified analysis of treatment modalities).










	AUC	95%CI	Specificity	Sensitivity	P value
Model 1	0.762	0.762 0.731-0.793		0.640	0.001
Model 2	0.822	0.796-0.849	0.729	0.742	



	Medical therapy			Endovascu	lar therapy		Intravenous	thrombolysis	
	Model 1	Model 2	P value	Model 1	Model 2	P value	Model 1	Model 2	P value
AUC	0.756	0.812	0.001	0.740	0.872	0.001	0.849	0.888	0.062
95%CI low	0.710	0.772		0.686	0.835		0.781	0.826	
95%CI upp	0.802	0.852		0.793	0.909		0.917	0.950	
Specificity	0.665	0.697		0.759	0.819		0.764	0.865	
Sensitivity	0.733	0.795		0.635	0.756		0.818	0.818	